Pembrolizumab vs ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Source: MDLinx, August 2019

Researchers describe findings after a 5-year follow-up among participants of an open-label, multicenter, randomized, controlled, phase 3 study assessing pembrolizumab vs ipilimumab in patients with advanced melanoma. Ipilimumab-naive patients with advanced melanoma with known BRAF V600 status and up to one previous systemic therapy with Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly allocated (1:1:1) to intravenous pembrolizumab 10 mg/kg every 2 weeks or every 3 weeks or four doses of intravenous ipilimumab 3 mg/kg every 3 weeks.